Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlycoVaxyn has appointed Philippe Dro as its new CEO and member of the supervisory board.
Subscribe to our email newsletter
Most recently, Mr Dro was chairman and CEO of Endoart, a medtech company developing telemetric driven implants for cardiac disease and obesity, which was sold to Allergan.
Mr Dro earned a Pharm D from University of Grenoble (France) and an MBA jointly from Ecole Superieure de Commerce de Lyon (France) and Cranfield School of Management (UK).
Michel Greco, chairman of GlycoVaxyn, said: “Philippe’s extensive experience working with emerging companies in strategic, business and commercial development capacities will prove extremely valuable to GlycoVaxyn.”